Amino Acid Sequence
Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-derived backbone with non-standard residues and a fatty diacid attached to a lysine side chain. The authoritative residue-level sequence is in the primary characterisation paper.
Key concepts
- 39 residues, single chain, GIP-derived backbone
- Non-standard residues confer enzymatic stability
- Fatty diacid on a lysine side chain drives albumin binding
- Third-party reproduced sequences are often wrong — use the primary paper
- Mass spectrometry, not illustration, is the basis for sequence verification
What the sequence is based on
The backbone derives from GIP rather than from GLP-1 or glucagon, which is a useful corrective to the common assumption that anything in this field starts from the GLP-1 template. Substitutions were then introduced to add GLP-1 and glucagon receptor activity while retaining GIP receptor potency.
Several residues are non-standard amino acids. Their role is to resist enzymatic cleavage and to fine-tune receptor selectivity, and they are the reason the molecule cannot be reproduced by recombinant expression of standard residues alone.
Lipidation and its position
A fatty diacid is attached to a lysine side chain in the mid-region of the chain. The attachment site is deliberate: it promotes reversible albumin binding without obstructing the receptor-binding regions at the chain termini.
This is the structural basis of the extended duration of action reported for the molecule and the reason it is studied on a weekly rather than daily schedule.
| Feature | Detail |
|---|---|
| Chain length | 39 amino acids, single unbranched chain |
| Backbone origin | GIP-derived |
| Non-standard residues | Present; improve enzymatic stability |
| Lipid conjugate | Fatty diacid on a lysine side chain |
| Synthesis route | Solid-phase peptide synthesis |
Where to read the verified sequence
Residue-by-residue sequences reproduced on third-party websites are frequently inaccurate. The characterisation paper by Coskun and colleagues is the appropriate primary source, and a batch certificate of analysis is the appropriate check on supplied material.
Illustrations on this site, including the schematic above, are indicative of structural class and are not a substitute for that published sequence.
Distinguishing verified sequence data from illustration
Diagrams and schematics, including the one on this page, are illustrative aids for explaining structural class — chain length, backbone origin, presence of non-standard residues and a lipidation site — and are explicitly not intended to convey exact residue identity or position. Treating a schematic as a literal sequence is a common source of error in secondary summaries.
The distinction matters because non-standard residues in particular are easy to render incorrectly in illustration, and their specific chemistry is part of what confers enzymatic stability. Any research use of sequence information should trace back to the primary characterisation paper rather than to an illustrative diagram.
Sequence verification of supplied material
Confirming that a supplied peptide matches the intended sequence, rather than a truncated or substituted variant, relies on mass spectrometry to check overall mass and, where available, tandem mass spectrometry or Edman-type sequencing to check specific residues. Chromatographic purity from HPLC is a separate and complementary measurement.
A shift in measured mass relative to the expected value, even a small one, generally indicates a sequence-level difference such as a missing or substituted residue, incomplete lipidation, or an oxidation event, rather than measurement noise, and should prompt a repeat analysis rather than being disregarded.
Why the backbone origin is worth restating
Because retatrutide is frequently discussed alongside GLP-1-class compounds, it is worth restating that its backbone is derived from GIP rather than GLP-1. This affects not only receptor pharmacology but also which prior peptide engineering literature is actually relevant background reading — GIP receptor and GIP analogue literature is more directly informative than GLP-1 analogue literature for understanding the base sequence.
Reconstitution and handling consequences of the lipidation site
The lysine-linked fatty diacid that defines retatrutide’s sequence also determines aspects of how supplied material should be reconstituted. Because the conjugate increases the molecule’s tendency to adsorb to plastic surfaces and to foam under agitation, reconstitution protocols for lipidated peptides of this kind typically specify gentle swirling rather than vortexing, and low-protein-binding labware where volumes are small enough for surface adsorption to matter.
These handling points follow directly from the sequence-level design rather than being arbitrary laboratory convention: a peptide without a lipid conjugate would not show the same foaming or adsorption behaviour, so understanding the sequence helps explain why retatrutide’s handling recommendations differ from those for a simple unmodified peptide of similar length.
Searching the primary literature for sequence-level data
Because reproduced sequences on secondary websites are a known source of error, an efficient way to confirm sequence-level claims is to search PubMed directly for the development code LY3437943 together with terms such as sequence, structure or characterisation, rather than searching for retatrutide sequence alone, which more often surfaces secondary summaries than the primary paper.
Where a specific residue position or modification needs to be checked for an experimental design, consulting the methods and supplementary material of the primary characterisation paper, rather than a schematic or a table on a secondary site, is the appropriate step, since supplementary material in primary papers is more likely to include the analytical evidence supporting a specific sequence claim.
Strength of the current evidence
Structural class and design features are documented. Residue-level detail should be taken only from the primary characterisation literature.
References
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022 (PubMed)
- Eli Lilly clinical development pipeline (Eli Lilly)
Related Retatrutide research
- Molecular Structure — Sequence features, lipidation and structural modifications that define the retatrutide molecule.
- Molecular Weight — Reported molecular weight of retatrutide, how it is confirmed analytically, and how to use it in reconstitution calculations.
- Retatrutide Receptors — The three receptors retatrutide is designed to activate, what each one does, and why the balance between them defines the molecule.
- Retatrutide Peptide Profile — Reference profile for retatrutide as a peptide: designation, class, receptor targets, format and batch testing.
Back to the Retatrutide research hub · Retatrutide research material · Certificates of analysis
Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.